We identified a fluorophore, 1-aminoanthracene (1-AMA), that is anesthetic, potentiates GABAergic transmission, and gives an appropriate dissociation constant, Kd Ϸ 0. ferritin ͉ probe ͉ GABA ͉ propofol ͉ imaging
D
espite controlled administration by trained physicians, current general anesthetics are still responsible for morbidity and mortality (1, 2) . Reports are also emerging that durable cognitive effects may occur from anesthesia, in particular, in the elderly (3) (4) (5) and very young (6) (7) (8) , and repeated exposure may hasten the onset of neurodegenerative disease (9) (10) (11) . Several factors have slowed efforts to identify safer and more effective anesthetics, not least of which is the large number (Ϸ10 60 ) of candidate molecules with molecular mass Յ500 g/mol (12) . It is also problematic that the most relevant molecular targets of clinical anesthetics have not been definitively assigned, and their in vivo distribution is poorly understood. Fluorescent probes offer the potential to address these problems, with the caveat that tethering a fluorophore to the typically small anesthetic is likely to eliminate its activity. This motivated our search for an intrinsically fluorescent general anesthetic.
Common general anesthetics are thought to act on membrane receptor proteins such as ion channels (13) , which are large, water insoluble, and difficult to obtain in pure form; they contain many interacting small-molecule binding sites. Thus, screening small-molecule libraries by using putative anesthetic receptors is not currently feasible. Recently, we identified a high-affinity general anesthetic binding site on a readily available, watersoluble protein, horse spleen apoferritin (HSAF) (14) . HSAF is comprised of 24 four-helix bundle subunits that self-assemble to form a protein shell with 4,3,2-symmetry, which functions to sequester iron as ferric hydroxide (15, 16) . Crystal structures of HSAF complexed with isoflurane or halothane show that the anesthetics bind in single Ϸ400 Å 3 hydrophobic cavities formed at the interfaces between pairs of four-helix bundle subunits (14) . Ferritin exhibits striking architectural similarities to the transmembrane region of the superfamily of ligand-gated channels, such as the GABA A receptor, which is a pentamer of 4-␣-helix bundles, with the proposed anesthetic site at the interhelical, subunit interface ( Fig. 1) (17) . The strength of small-molecule binding interactions with HSAF correlates well with anesthetic potency (supporting information (SI) Fig. S1 ). These features recommend HSAF as a potential model protein receptor for screening fluorescent probes and new drug candidates.
We identified the fluorophore 1-aminoanthrancene (1-AMA) as a general anesthetic by searching for probe molecules that bind HSAF and compete with known anesthetics. 1-AMA is a polarity-sensitive hydrophobic probe that has been used previously to investigate different protein cavities (18) (19) (20) (21) . We report that 1-AMA shows enhanced fluorescence intensity at 515 nm when complexed with HSAF. Binding to the HSAF site of interest is indicated by a large decrease in 1-AMA fluorescence on addition of general anesthetics. This suggests that a fluorescence assay based on 1-AMA and HSAF should be useful for compound screening. Interestingly, 1-AMA has physicochemical properties similar to propofol, a common i.v. general anesthetic: They are similar in molecular mass (193 g/mol for 1-AMA vs. 178 g/mol for propofol), hydrophobicity as measured by log 10 of the octanol/water partition coefficient (log P ϭ 3.7 vs. 3.8), and polar surface area (26 cm 2 vs. 20 cm 2 ) (22) . Moreover, 1-AMA was found to potentiate GABA-induced chloride transport in isolated cells, induce reversible immobility in Xenopus tadpoles, and enable in vivo fluorescence imaging studies, which show localization in neuronal tissue.
Results
Measuring 1-AMA Binding to HSAF. We determined that small organic solubilizing agents such as MeOH compete with 1-AMA binding to HSAF, in agreement with previous 1-AMA studies (19) . Thus, to 1-mL solutions of 1-AMA in 10% PEG-400 and PBS buffer (final concentration, 1-220 M) was added 20 L of HSAF (final concentration, 1.55 M 24-mer, 18.6 M dimer). Emission data were corrected for contributions from 1-AMA and HSAF alone in 10% PEG-400 and PBS buffer. A dissociation constant, K d ϭ 70 Ϯ 20 M (95% confidence limit) at 298 K, was determined for data points up to 220 M 1-AMA by curve fitting to a single-site binding model (Fig. 2) ,
where ). Because of 1-AMA's limited water solubility, a reverse titration was performed, whereby 0.67 mM HSAF in 10% PEG-400 in PBS was titrated into an ITC cell containing a saturated solution of 1-AMA in the same PEG-containing buffer. ITC provided a dissociation constant for the HSAF-1-AMA complex (K d ϭ 96 Ϯ 11 M at 298 K; Fig. 3 ), which was in good agreement with the fluorescence data and confirmed 1-AMA binding. As seen in Figs. 2 and 3, modest solubility of 1-AMA in 10% PEG-400 and PBS buffer prevented complete saturation of HSAF binding sites.
Evidence of 1-AMA occupation of the HSAF anesthetic site, instead of an allosterically coupled remote site, comes from molecular docking and energy minimization approaches showing 1-AMA binding without significant distortion or steric clash at the anesthetic site (Fig. 1 ). During energy minimization, 1-AMA rotated in the HSAF anesthetic cavity, which was accommodated by adjustment of both Arg-59 residues at the 2-fold symmetric interface. The conformation of these Arg-59 residues at the cavity mouth has previously been shown to be A B C sensitive to occupancy of this cavity (14) . Although the effective cavity size may consequently be larger when occupied by 1-AMA than with halothane, all residues besides Arg-59 remained virtually stationary.
Measuring Isoflurane and Propofol Binding to HSAF by 1-AMA Displacement. To further confirm binding at the anesthetic site on HSAF, a competition assay was performed by using isoflurane, a clinical anesthetic that has been confirmed crystallographically to bind at the HSAF anesthetic site (14) . As isoflurane was titrated, the fluorescence signal from 1-AMA (Fig. 4 Left) decreased in a manner well fit by a single-site binding model (Eq. 1, Fig. 4 Right). Curve fitting to the Hill equation identified an IC 50 for isoflurane of 270 M Ϯ 30 M at 298 K, which was corrected by using the Cheng-Prusoff equation, (20) . This is comparable to the value determined for isoflurane by direct measurement by using ITC and assuming a single class of sites (14) . These data provide strong evidence that 1-AMA also binds to the HSAF anesthetic site.
We subsequently investigated the use of the 1-AMA/HSAF competition assay in a higher-throughput, 96-well plate format. Propofol is an oily GABAergic general anesthetic with only moderate volatility, which makes it possible to control concentrations in an open system. Propofol displaced 1-AMA with an IC 50 of 11 M (95% CI ϭ 7-17 M) and Hill slope of Ϫ0.8 (95% CI ϭ Ϫ1.1 to Ϫ0.6) (Fig. S2) . The calculated K d of 10 M (Eq. 2) is similar that obtained by ITC, and is a reasonable approximation of the EC 50 observed to enhance GABA A currents and produce anesthesia in vivo (13) . This provides further validation of the GABA A mimicry by the apoferritin site, and demonstrates the utility of 1-AMA to study compound binding to the HSAF anesthetic site.
Anesthetic Functional Assays. Having validated 1-AMA from HSAF binding studies and competition assays as a likely anesthetic candidate, the anesthetic potency of 1-AMA was verified in Xenopus tadpoles by measuring the startle reflex. At the highest concentration achievable in pond water (Ϸ33 M), almost all animals lost their startle reflex within 15-20 min (Fig.  5) . Based on this assay, the EC 50 for 1-AMA was 16 M (95% C.I. ϭ 8-34 M), and Hill slope of 1.4 (95% C.I. ϭ 0.1-3.0). Most tadpoles recovered fully but slowly from the immobilized state when returned to pure pond water. However, Ϸ50% of the tadpoles that had been exposed to the highest 1-AMA concentrations subsequently died over a period of hours, most likely due to toxic metabolites of 1-AMA (23) .
Most general anesthetics in use today are positive modulators of GABA A receptors-i.e., they enhance responses to application of their naturally occurring agonist, ␥-aminobutyric acid (GABA). Fig. 6 clearly shows that 1-AMA shares this feature in a heterologous expression system. Consistent with the observation that 1-AMA solubility is lower than its HSAF K d , and therefore probably the GABA A receptor K d as well, there was no evidence of saturation of receptor potentiation at concentrations up to 30 M 1-AMA.
1-AMA in Vivo Fluorescence
Imaging. Albino tadpoles immobilized with 1-AMA (Ϸ33 M) were imaged by using confocal laser scanning microscopy to determine anesthetic distribution in vivo, as well as subcellular localization. Whereas the few volatile general anesthetics in current clinical use that have been studied (i.e., halothane, sevoflurane) are promiscuous and distribute broadly (24), 1-AMA was observed to localize primarily in Xenopus neuronal tissue (Fig. 7) , with weak fluorescence also observed in the heart (Fig. S3) and other organs. These in vivo fluorescence intensities are readily assigned to 1-AMA, as opposed to cellular autofluorescence. Fluorescence was observed immediately and did not vary during imaging, which discounts contributions from 1-AMA metabolites. The in vivo fluorescence spectrum (broad emission peak with maximum Ϸ520 nm) matches that of 1-AMA in a low dielectric environment. Moreover, images taken by using the same confocal microscope settings on Xenopus immobilized with propofol show no fluorescence signal (Fig. S4) . Highresolution confocal optical sections taken with a 40ϫ objective lens show the subcellular localization of 1-AMA within a neuron in the tadpole brain (Fig. 8) . 1-AMA is localized to the nucleus broadly distributed within the neuron, whereas it appears more faintly at the nuclear membranes in the adjoining cells.
Discussion
The isoflurane and propofol competition studies, as well as 1-AMA modeling data presented herein strongly indicate that 1-AMA binds in the anesthetic site. Moreover, displacement of 1-AMA by propofol supports the GABA A mimicry of HSAF. These data suggest the use of this 1-AMA/HSAF assay for screening new compounds, which should allow a more complete investigation of steric and electronic factors that contribute to drug binding, while correlating the strength of these interactions with anesthetic potency.
Fluorescence-based binding assays offer large advantages in speed and sensitivity over methods such as isothermal titration calorimetry. One limitation has been that many common fluorophores incorporate substituted aromatic moieties and have molecular volumes exceeding the volume of the HSAF anesthetic site. Similar volume limitations are known to be relevant for genuine anesthetic targets, because clinical anesthetic potency falls off dramatically at molecular masses Ͼ180 g/mol (i.e., dodecanol in the n-alkanol series) (25) . This is consistent with initial experiments with the f luorophore ANS (molecular mass ϭ 299 g/mol), which showed no change in fluorescence signal on the addition of HSAF, likely because of its large size. By comparison, 1-AMA shows great promise as an HSAF binder and anesthetic probe molecule, based on its solvachromatic properties and modest molecular size.
The GABA enhancement observed at 30 M 1-AMA was large (Ϸ13-fold), suggesting a robust GABAergic effect at 1-AMA's solubility limit, and consistent with the in vivo EC 50 being somewhat below this concentration. Thus, 1-AMA shares in vitro features of many contemporary general anesthetics, such as propofol (26) , lending further credibility to the use of an HSAF/1-AMA assay for compound screening and discovery.
Given this GABAergic character, the localization of 1-AMA to neuronal tissue is best explained by selectivity to the ligandgated ion channel superfamily, although other neuronal targets, such as G protein-coupled receptors (20, 26) cannot be ruled out. The distribution within the tadpole head seems inconsistent with simple lipid distribution, because it would have been expected to distribute much more broadly. This provides additional support for the notion that specific neuronal proteins are the direct targets for general anesthetics.
Interestingly, confocal micrographs of the tadpole brain (Fig.  7) show nonuniform 1-AMA fluorescence intensity, which is likely due to the variable distribution of specific and nonspecific anesthetic sites within the brain. Localization in the cerebral lobe of the brain might arise because of the high density of synaptic contacts and associated signaling systems (27) . This finding agrees with previous studies of the rat brain, in which regions with high concentrations of anesthetic were correlated with high synaptic density (gray matter) (28) and unidentified macromolecular receptors (29) . By using standard confocal laser scanning microscopy imaging systems and light sources, it should be possible to use 1-AMA for understanding the distribution and modulation of anesthetic targets. At the excitation wavelength (488 nm) at which most of the present confocal imaging studies in tadpoles were conducted, 1-AMA has trace absorbance ( The lack of 1-AMA fluorescence from many parts of the tadpole suggests that ferritin itself contributes little to the distribution of the observed signal. Ferritin has been identified in all animal tissues, with highest concentrations usually found in liver, spleen, and bone marrow (30) . Although iron is an important element for the central nervous system, excessive brain iron is neurotoxic, and via Fenton chemistry produces free radicals that can cause oxidative damage of different cellular components. This may explain why ferritin concentrations in the healthy brain are typically low (31) .
Biological ferritin sequesters iron as a ferric oxide mineral core, which has little effect on 1-AMA binding but appears to quench approximately half of the fluorescence intensity (Fig.  S7) , likely by an electron-transfer process. Moreover, 488-nm excitation of 1-AMA bound to horse spleen ferritin (HSF) or HSAF in a cuvette produces only a weak fluorescent signal Ϸ520 nm (Fig. S8) . Thus, ferritin is expected to contribute very little to the 1-AMA fluorescence observed in the tadpole brain.
Previous efforts to image the distribution of clinical anesthetics in laboratory animals made use of signals from the available carbon and halogen atoms. For example, 14 C-halothane was quantified by autoradiography in fixed sections of the rat brain, where the volatile anesthetic was immobilized by photolabeling (28) or sample freezing (32, 33) . And, the distribution of sevoflurane in the head of a live rat was measured by 19 F NMR imaging (29) . Fluorescence imaging is a very sensitive and rapid technique, and provides much better spatiotemporal resolution than can be achieved by using autoradiography or NMR. As a demonstration, the confocal micrographs of 1-AMA in a tadpole represent the first high-resolution images of a general anesthetic distribution in an immobilized, living animal. Moreover, as shown in Fig. 8 , it is possible to obtain much higher resolution images of 1-AMA in neurons within the brain of the living tadpole. This image raises interesting questions about the interactions of 1-AMA with the cellular and nuclear membranes, and other membranes within the cell, where anesthetics are proposed to bind GABA A and other ligand-gated receptors.
In summary, 1-AMA binds to a site on HSAF (K d Ϸ 0.1 mM) with comparable affinity as other known anesthetic molecules, and provides a useful measure of unknown compound binding through competition assays. We found that 1-AMA is a fluorescent, GABAergic general anesthetic, which provides avenues for imaging anesthetic activity with unprecedented spatial and temporal resolution. The favorable fluorescence properties of 1-AMA coupled with HSAF's high level of structural mimicry of relevant regions of ligand-gated ion channels, aqueous solubility, ready availability, and ease of crystallization and structure determination, make this combination an ideal high-throughput system for the determination of potentially new classes of anesthetic molecules.
Methods
See SI Text for detailed methods and data.
Molecular Docking of 1-AMA. A likely orientation for 1-AMA in the HSAF cavity was determined by manually docking 1-AMA into the cavity by using VMD (34) , and then energy minimizing the ligand and protein side chains according to the CHARMM-22 force field (35) . The initial coordinates for the HSAF 4-helix bundle subunit were taken from the X-ray structure in the presence of halothane (PDB ID code 1XZ1) (14) .
UV-Vis Spectroscopy. All UV-Vis measurements were made with an Agilent Technologies 8453 spectrophotometer with 89090A temperature controller and magnetic stirrer, using a quartz cuvette with 1-cm pathlength. 1-AMA stock solutions were made by using 368 ϭ 4,240 M Ϫ1 cm Ϫ1 . The concentration of pure HSAF 24-mer was determined by both Bradford assay and UV-Vis spectroscopy.
Fluorescence Spectroscopy. 1-AMA was excited at 380 nm and fluorescence data were collected from 390 to 720 nm by using a Cary Eclipse fluorescence spectrophotometer (Varian) and the Cary Eclipse Bio software package.
GABAA Electrophysiological Recordings.
Cells were cultured and transfected as described in SI Text. Recordings were performed at room temperature on the stage of a Leica inverted microscope. Solutions were applied to lifted wholecells by using a custom-designed 12-barrel application system. An open-tip solution exchange time constant () of 20 -30 ms was typically achieved. The recording chamber was perfused continuously with HEPES-buffered saline. GABA solutions were diluted to the desired concentration (4 M) in this same control/bath solution. 1-AMA solutions were added in the same buffer, at the concentrations shown in Fig. 6 .
